
NUCLIDIUM Begins Phase 1 Study of 61Cu Radiotracer in PSMA-Positive Prostate Cancer
NUCLIDIUM has announced the successful imaging of its first patient in a Phase 1 clinical trial for its radiotracer candidate, aimed at providing a safe and accurate diagnostic tool for prostate cancer. The radiotracer, 61Cu-NuriPro™ (61Cu-NODAGA-PSMA I&T), targets Prostate Specific…












